U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H50N6O5
Molecular Weight 670.8422
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SAQUINAVIR

SMILES

CC(C)(C)N=C([C@]1([H])C[C@]2([H])CCCC[C@]2([H])CN1C[C@]([H])([C@]([H])(Cc3ccccc3)N=C([C@]([H])(CC(=N)O)NC(=O)c4ccc5ccccc5n4)O)O)O

InChI

InChIKey=QWAXKHKRTORLEM-UGJKXSETSA-N
InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1

HIDE SMILES / InChI

Molecular Formula C38H50N6O5
Molecular Weight 670.8422
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: https://www.drugbank.ca/drugs/DB01232 | http://reference.medscape.com/drug/invirase-saquinavir-342628 | https://www.drugs.com/cdi/saquinavir.html | https://www.ncbi.nlm.nih.gov/pubmed/20950334

Saquinavir (brand names Invirase and Fortovase) is an antiretroviral drug used together with other medications to treat or prevent HIV/AIDS. Saquinavir is an inhibitor of HIV protease. HIV protease is an enzyme required for the proteolytic cleavage of viral polyprotein precursors into individual functional proteins found in infectious HIV. Saquinavir is a peptide-like substrate analog that binds to the protease active site and inhibits the activity of the enzyme. Saquinavir inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature noninfectious virus particles. The most frequent adverse events with saquinavir in either formulation are mild gastrointestinal symptoms, including diarrhea, nausea, loose stools & abdominal discomfort. Invirase is better tolerated than Fortovase.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.5 nM [IC50]
0.400000000000000022 nM [IC50]
0.400000000000000022 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FORTOVASE

Approved Use

INDICATIONS & USAGE INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV-1 infection in adults (over the age of 16 years). The following points should be considered when initiating therapy with INVIRASE: – The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 trial [see Adverse Reactions (6.1)

Launch Date

878860800000
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
21747 ng × h/mL
1200 mg 3 times / day steady-state, oral
dose: 1200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SAQUINAVIR unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Other AEs: Diabetes mellitus, Lipodystrophy...
Other AEs:
Diabetes mellitus (3%)
Lipodystrophy (5%)
Nausea (11%)
Vomiting (7%)
Diarrhea (8%)
Abdominal pain (6%)
Constipation (2%)
Fatigue (6%)
Fever (3%)
Back pain (2%)
Pneumonia (5%)
Bronchitis (3%)
Influenza (3%)
Sinusitis (3%)
Rash (3%)
Pruritus (3%)
Dry lips (2%)
Eczema (2%)
Sources:
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (22.2%)
Vomiting (6.2%)
Diarrhea (4.9%)
Abdominal pain (2.5%)
Diarrhea aggravated (2.5%)
Esophageal reflux (2.5%)
Fatigue (2.5%)
Dizziness (excl vertigo) (1.2%)
Dermatitis (1.2%)
Decreased appetite (3.7%)
Headache (2.5%)
Insomnia (1.2%)
Weakness (2.5%)
Depression (2.5%)
Anxiety (1.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea 11%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Back pain 2%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Constipation 2%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Dry lips 2%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Eczema 2%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Bronchitis 3%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Diabetes mellitus 3%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Fever 3%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Influenza 3%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Pruritus 3%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Rash 3%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Sinusitis 3%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Lipodystrophy 5%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Pneumonia 5%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Abdominal pain 6%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Fatigue 6%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Vomiting 7%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Diarrhea 8%
1000 mg 2 times / day multiple, oral
Recommended
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources:
unhealthy, adult
Anxiety 1.2%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Dermatitis 1.2%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Dizziness (excl vertigo) 1.2%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Insomnia 1.2%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Abdominal pain 2.5%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Depression 2.5%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Diarrhea aggravated 2.5%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Esophageal reflux 2.5%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Fatigue 2.5%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Headache 2.5%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Weakness 2.5%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Nausea 22.2%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Decreased appetite 3.7%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Diarrhea 4.9%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Vomiting 6.2%
1600 mg 1 times / day multiple, oral
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
little [IC50 >100 uM]
little [IC50 >100 uM]
little [IC50 >100 uM]
negligible [IC50 >100 uM]
negligible [IC50 >100 uM]
weak [Ki 1.8 uM]
yes [IC50 1.8 uM]
yes [IC50 13 uM]
yes [IC50 2.1 uM]
yes [IC50 2.14 uM]
yes [IC50 27.4 uM]
yes [IC50 4.1 uM]
yes [IC50 5.3 uM]
yes [IC50 5.5 uM]
yes [IC50 54 uM]
yes [IC50 8 uM]
yes [IC50 8.3 uM]
yes [Ki 0.6 uM]
yes [Ki 24 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 <10 uM]
yes
yes
yes
yes (co-administration study)
Comment: Coadministration with ritonavir (CYP3A4 inhibitor): mean saquinavir AUC value was seven fold greater than mean value observed after administration of saquinavir alone.
Page: 13,19
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Saquinavir soft gelatin capsule: a comparative safety review.
2001
Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.
2001
Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.
2001 Apr
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
2001 Apr
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
2001 Apr 10
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
2001 Apr 13
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.
2001 Apr 13
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.
2001 Apr 15
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
2001 Apr 15
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.
2001 Apr 15
[Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].
2001 Apr 2
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
2001 Aug
Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.
2001 Aug
Antiviral drugs: current state of the art.
2001 Aug
Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
2001 Aug 1
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
2001 Aug 1
HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
2001 Aug 1
[Resistance to protease inhibitors].
2001 Feb
Pharmacology and clinical experience with saquinavir.
2001 Feb
New developments in anti-HIV chemotherapy.
2001 Jan-Feb
Structure-based design of non-peptide HIV protease inhibitors.
2001 Jan-Feb
Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model.
2001 Jul
Predictors of protease inhibitor-associated adverse events.
2001 Jul
HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.
2001 Jul
Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.
2001 Jul
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.
2001 Jul
Capillary electrophoretic separation of protease inhibitors used in human immunodeficiency virus therapy.
2001 Jul 13
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.
2001 Jul 15
Synthesis of a chiral aziridine derivative as a versatile intermediate for HIV protease inhibitors.
2001 Jul 26
The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
2001 Jun
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
2001 Jun
Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998.
2001 Jun 1
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.
2001 Jun 1
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
2001 Jun 1
Design and synthesis of a conformationally restricted trans peptide isostere based on the bioactive conformations of saquinavir and nelfinavir.
2001 Jun 1
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
2001 Jun 15
A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans.
2001 Mar
Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study.
2001 Mar
The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients.
2001 May
Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
2001 May
Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.
2001 May
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.
2001 May
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
2001 May 25
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
2001 May 4
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
2001 May 5
Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir.
2001 May 7
[Drug interactions with antiretroviral agents].
2001 May-Jun
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.
2001 Sep
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
2001 Sep 14
Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR.
2001 Sep 7
Patents

Sample Use Guides

1000 mg (with ritonavir 100 mg) PO q12hr, or in combination with ritonavir-enhanced lopinavir
Route of Administration: Oral
In vitro antiviral activity of saquinavir was assessed in lymphoblastoid and monocytic cell lines and in peripheral blood lymphocytes. Saquinavir inhibited HIV activity in both acutely and chronically infected cells. IC50 and IC90 values (50% and 90% inhibitory concentrations) were in the range of 1 to 30 nM and 5 to 80 nM, respectively. In the presence of 40% human serum, the mean IC50 of saquinavir against laboratory strain HIV-1 RF in MT4 cells was 37.7± 5nM representing a 4-fold increase in the IC50 value. In cell culture, saquinavir demonstrated additive to synergistic effects against HIV-1 in combination with reverse transcriptase inhibitors (didanosine, lamivudine, nevirapine, stavudine, zalcitabine and zidovudine) without enhanced cytotoxicity. Saquinavir in combination with the protease inhibitors amprenavir, atazanavir, or lopinavir resulted in synergistic antiviral activity. Saquinavir displayed antiviral activity in vitro against HIV-1 clades A-H (IC50 ranged from 0.9 to 2.5 nM). The IC50 and IC90 values of saquinavir against HIV-2 isolates in vitro ranged from 0.25 nM to 14.6 nM and 4.65 nM to 28.6 nM respectively.
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:35:49 UTC 2021
Edited
by admin
on Sat Jun 26 04:35:49 UTC 2021
Record UNII
L3JE09KZ2F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SAQUINAVIR
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
RO 31-8959/000
Code English
SAQUINAVIR [JAN]
Common Name English
SAQUINAVIRUM [WHO-IP LATIN]
Common Name English
SAQUINAVIR [ORANGE BOOK]
Common Name English
SAQUINAVIR [VANDF]
Common Name English
SAQUINAVIR [USAN]
Common Name English
SAQUINAVIR [HSDB]
Common Name English
RO-31-8959/000
Code English
BUTANEDIAMIDE, N(SUP 1)-(3-(3-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)OCTAHYDRO-2(1H)-ISOQUINOLINYL)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-2-((2-QUINOLINYLCARBONYL)AMINO)-, (3S-(2(1R*(R*),2S*),3.ALPHA.,4A.BETA.,8A.BETA.))-
Common Name English
(S)-N-((IS)-I-((1R)-2-((3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)OCTAHYDRO-2(1H)-ISOQUINOLYL)-1-HYDROXYETHYL)PHENETHYL)-2-QUINALDAMIDOSUCCINAMIDE
Common Name English
SAQUINAVIR [USP]
Common Name English
SAQUINAVIR [WHO-IP]
Common Name English
SAQUINAVIR [WHO-DD]
Common Name English
SAQUINAVIR [EMA EPAR]
Common Name English
(S)-N-((.ALPHA.S)-.ALPHA.-((1R)-2-((3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)OCTAHYDRO-2(1H)-ISOQUINOLYL)-1-HYDROXYETHYL)PHENETHYL)-2-QUINALDAMIDOSUCCINAMIDE
Common Name English
SAQUINAVIR [INN]
Common Name English
SAQUINAVIR [MART.]
Common Name English
SCH-52852
Code English
SAQUINAVIR [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175889
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
NDF-RT N0000000246
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
WHO-VATC QJ05AE01
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
EMA ASSESSMENT REPORTS INVIRASE (AUHTORIZED: HIV INFECTIONS)
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
EMA ASSESSMENT REPORTS FORTOVASE (WITHDRAWN: HIV INFECTIONS)
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
WHO-ATC J05AE01
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
NCI_THESAURUS C97366
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
LIVERTOX 871
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
Code System Code Type Description
INN
7098
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
NCI_THESAURUS
C29444
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
IUPHAR
4813
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
DRUG BANK
DB01232
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
WIKIPEDIA
SAQUINAVIR
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SAQUINAVIR
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water and soluble in methanol. Category: Antiretroviral (Protease Inhibitor). Storage: Saquinavir should be kept at 2-8?C in a tightly closed container, protected from light. Additional information: Saquinavir is slightly hygroscopic. Requirements: Saquinavir contains not less than 98.5 % and not more than 101.0 % of C38H50N6O5, calculated with reference to the dried substance.
FDA UNII
L3JE09KZ2F
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
ChEMBL
CHEMBL114
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
NDF-RT
N0000190114
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
DRUG CENTRAL
2422
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
EVMPD
SUB10446MIG
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
RXCUI
83395
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY RxNorm
PUBCHEM
441243
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
LACTMED
Saquinavir
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
MERCK INDEX
M9776
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY Merck Index
MESH
D019258
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
EPA CompTox
127779-20-8
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
HSDB
7161
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
CAS
127779-20-8
Created by admin on Sat Jun 26 04:35:50 UTC 2021 , Edited by admin on Sat Jun 26 04:35:50 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SUBSTRATE USED: ESTRONE-3-SULFATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC